Klaria Pharma Holding AB AI Stock Analysis
Klaria Pharma Holding AB (6FN) AI Stock Analysis
Klaria Pharma Holding AB
(Frankfurt:6FN)
No summary available
Klaria Pharma Holding AB (6FN) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 11.12M
- Dividend Yield
- ―
- Average Volume (3M)
- 750
- Price to Earnings (P/E)
- -3.0
- Beta (1Y)
- 1.12
- Revenue Growth
- -98.95%
- EPS Growth
- 36.43%
- Country
- Germany
- Employees
- 4
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Klaria Pharma Holding AB Business Overview & Revenue Model
Company Description
Klaria Pharma Holding AB (publ.) functions as a pharmaceutical enterprise, active both in Sweden and across global territories. Its current portfolio features Sumatriptan for migraine management and Midazolam for combating acute epileptic seizures. W...
Klaria Pharma Holding AB Peers Comparison
Overall Rating
SE:ALZCUR48.1Neutral
SE:ELIC48Neutral
SE:ISOFOL48Neutral
SE:XBRANE46Neutral
SE:IRLAB.A38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | SEK 882.54M | 10.67 | 105.09% | ― | ― | ― | |
| 48Neutral | SEK 172.51M | -7.31 | -56.09% | ― | ― | 14.10% | |
| 48Neutral | SEK 326.26M | -5.09 | -58.68% | ― | ― | 35.02% | |
| 46Neutral | SEK 235.93M | -6.34 | -11.52% | ― | -38.80% | -120.18% | |
| 38Underperform | SEK 126.11M | -1.30 | -97.06% | ― | -21.20% | 68.24% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:6FN | Klaria Pharma Holding AB | 0.04 | 0.00 | 5.41% | |
| SE:ALZCUR | AlzeCure Pharma AB | 6.40 | 4.54 | 243.16% | |
| SE:XBRANE | Xbrane Biopharma AB | 11.45 | 1.39 | 13.82% | |
| SE:ISOFOL | Isofol Medical AB | 1.02 | 0.32 | 45.85% | |
| SE:ELIC | Elicera Therapeutics AB | 2.58 | -2.68 | -50.86% | |
| SE:IRLAB.A | IRLAB Therapeutics AB Class A | 0.85 | -1.37 | -61.82% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
